Clinical Trial: A 32-week Trial to Evaluate the Efficacy and Safety of Tralokinumab in Subjects With Moderate-to-severe Atopic Hand Eczema Who Are Candidates for Systemic Therapy
Study Status: COMPLETED
Recruit Status: COMPLETED
Condition: Atopic Dermatitis
Study Type: INTERVENTIONAL
Official Title: A Phase 3b, Interventional, Adaptive, Clinical Trial to Evaluate the Efficacy and Safety of Tralokinumab 300 mg Every Second Week Monotherapy Compared With Placebo in Subjects With Moderate-to-severe
Brief Summary:
The purpose of this study is to test if treatment with tralokinumab is safe and effectful to treat moderate-to-severe atopic hand eczema.This will be judged by a range of assessments that rate the severity and extent of atopic hand eczema and its symptoms, as well as general health status and quality of life.The trial will last for up to 40 weeks.There will be up to 15 visits, 3 of which will be conducted by phone.The first part of the trial is called a screening period and will last up to 4 weeks.For the first 16…
Read more